Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 2/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | DRD1 | P21728 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8970769 | 0.80 | SLC6A3 (0.56) | SLC6A3SIGMAR1ACHEDRD2HTR1A | |
| SCHEMBL6056974 | 0.79 | SLC6A3 (0.83) | SLC6A3SIGMAR1ACHEDRD2HTR1A | |
| SCHEMBL13150782 | 0.79 | SLC6A3 (0.83) | SLC6A3SIGMAR1ACHEDRD2HTR1A | |
| SCHEMBL7264546 | 0.79 | SLC6A3 (0.83) | SLC6A3SIGMAR1ACHEDRD2HTR1A | |
| SCHEMBL14407778 | 0.79 | SLC6A3 (0.83) | SLC6A3SIGMAR1ACHEDRD2HTR1A | |
| SCHEMBL27638865 | 0.79 | SLC6A3 (0.63) | SLC6A3SIGMAR1ACHEDRD2HTR1A | |
| SCHEMBL12668136 | 0.78 | SLC6A3 (0.68) | SLC6A3SIGMAR1ACHEDRD2HTR1A | |
| SCHEMBL11742308 | 0.77 | SLC6A3 (0.61) | SLC6A3SIGMAR1ACHEDRD2HTR1A | |
| SCHEMBL18838288 | 0.77 | SLC6A3 (0.67) | SLC6A3SIGMAR1ACHEDRD2HTR1A | |
| SCHEMBL8970787 | 0.77 | SLC6A3 (0.56) | SLC6A3SIGMAR1ACHEDRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | AFASCI, INC. (US) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | CACNA1I, CACNA1G, CACNA1H | SLC6A3 226/4885SIGMAR1 1097/4885ACHE 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.